

RESPONSE TO ELECTION  
OF SPECIES REQUIREMENT  
U.S. Appln. No. 09/961,086

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-4. (Cancelled).

Claim 5. (Previously Presented) An isolated antibody which binds to SEQ ID NO:1.

Claim 6. (Previously Presented) The isolated antibody of claim 5 which is monoclonal.

Claim 7. (Previously Presented) The isolated antibody of claim 5 which is polyclonal.

Claims 8-37. (Cancelled).

Claim 38. (Previously Presented) A pharmaceutical composition comprising an isolated antibody which binds to SEQ ID NO:1 and a pharmaceutically acceptable carrier or diluent.

Claim 39. (Withdrawn) A method of screening a sample for a polypeptide comprising the amino acid sequence of SEQ ID NO:1, said method comprising:

- (a) contacting a test sample with the antibody of claim 5, and
- (b) detecting binding of said antibody to said polypeptide, thereby screening a sample for a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

Claim 40. (Withdrawn) A method of reducing development of resistance to a chemotherapeutic agent in a patient, said method

RESPONSE TO ELECTION  
OF SPECIES REQUIREMENT  
U.S. Appln. No. 09/961,086

comprising administering the antibody of claim 5 to a patient in need of chemotherapy.

Claim 41. (Previously Presented) An isolated antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) the Walker A motif of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 79 to position 86 of SEQ ID NO:1;
- (b) the phosphopantetheine site of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 213 to position 227 of SEQ ID NO:1;
- (c) the first transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 396 to position 414 of SEQ ID NO:1;
- (d) the second transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 538 to position 554 of SEQ ID NO:1; and
- (e) the third transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 630 to position 647 of SEQ ID NO:1.

Claim 42. (Previously Presented) The isolated antibody of claim 41 which is monoclonal.

Claim 43. (Previously Presented) The isolated antibody of claim 41 which is polyclonal.

Claim 44. (Previously Presented) A pharmaceutical composition comprising an isolated antibody which binds to a

RESPONSE TO ELECTION  
OF SPECIES REQUIREMENT  
U.S. Appln. No. 09/961,086

polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) the Walker A motif of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 79 to position 86 of SEQ ID NO:1;
- (b) the phosphopantetheine site of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 213 to position 227 of SEQ ID NO:1;
- (c) the first transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 396 to position 414 of SEQ ID NO:1;
- (d) the second transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 538 to position 554 of SEQ ID NO:1; and
- (e) the third transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 630 to position 647 of SEQ ID NO:1, and a pharmaceutically acceptable carrier or diluent.

Claim 45. (Withdrawn) A method of screening a sample for a polypeptide comprising the amino acid sequence of SEQ ID NO:1, said method comprising:

- (a) contacting a test sample with the antibody of claim 41, and
- (b) detecting binding of said antibody to said polypeptide, thereby screening a sample for a

RESPONSE TO ELECTION  
OF SPECIES REQUIREMENT  
U.S. Appln. No. 09/961,086

polypeptide comprising the amino acid sequence of  
SEQ ID NO:1.

Claim 46. (Withdrawn) A method of reducing development of resistance to a chemotherapeutic agent in a patient, said method comprising administering the antibody of claim 41 to a patient in need of chemotherapy.

Claim 47. (Withdrawn) A method of reducing development of resistance to a chemotherapeutic agent in a patient, said method comprising administering the pharmaceutical composition of claim 44 to a patient in need of chemotherapy.

Claim 48. (Previously Presented) An isolated antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) the Walker A motif of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 79 to position 86 of SEQ ID NO:1;
- (b) the phosphopantetheine site of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 213 to position 227 of SEQ ID NO:1;
- (c) the first transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 396 to position 414 of SEQ ID NO:1;
- (d) the second transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 538 to position 554 of SEQ ID NO:1; and

RESPONSE TO ELECTION  
OF SPECIES REQUIREMENT  
U.S. Appln. No. 09/961,086

(e) the third transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 630 to position 647 of SEQ ID NO:1, wherein said antibody permits accumulation of daunorubicin in MCF-7 cells expressing a polypeptide having the amino acid sequence of SEQ ID NO:1.

Claim 49. (Previously Presented) The isolated antibody of claim 48 which is monoclonal.

Claim 50. (Previously Presented) The isolated antibody of claim 48 which is polyclonal.

Claim 51. (Previously Presented) A pharmaceutical composition comprising an isolated antibody which binds to a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) the Walker A motif of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 79 to position 86 of SEQ ID NO:1;
- (b) the phosphopantetheine site of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 213 to position 227 of SEQ ID NO:1;
- (c) the first transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 396 to position 414 of SEQ ID NO:1;
- (d) the second transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 538 to position 554 of SEQ ID NO:1; and

RESPONSE TO ELECTION  
OF SPECIES REQUIREMENT  
U.S. Appln. No. 09/961,086

(e) the third transmembrane domain of the polypeptide of SEQ ID NO:1, consisting of amino acid residues from position 630 to position 647 of SEQ ID NO:1, and a pharmaceutically acceptable carrier or diluent, wherein said antibody permits accumulation of daunorubicin in MCF-7 cells expressing a polypeptide having the amino acid sequence of SEQ ID NO:1.

Claim 52. (Withdrawn) A method of screening a sample for a polypeptide comprising the amino acid sequence of SEQ ID NO:1, said method comprising:

- (a) contacting a test sample with the antibody of claim 48, and
- (b) detecting binding of said antibody to said polypeptide, thereby screening a sample for a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

Claim 53. (Withdrawn) A method of reducing development of resistance to a chemotherapeutic agent in a patient, said method comprising administering the antibody of claim 48 to a patient in need of chemotherapy.

Claim 54. (Withdrawn) A method of reducing development of resistance to a chemotherapeutic agent in a patient, said method comprising administering the pharmaceutical composition of claim 51 to a patient in need of chemotherapy.